{"id":"fenretinide-lym-x-sorb-oral-powder","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fenretinide works by activating retinoic acid receptors, which leads to the induction of apoptosis in cancer cells. This process is thought to be mediated by the activation of caspases and the disruption of mitochondrial function.","oneSentence":"Fenretinide is a synthetic retinoid that induces apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:47.333Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT00295919","phase":"PHASE1","title":"N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2005-12","conditions":"Neuroblastoma","enrollment":80},{"nctId":"NCT02163356","phase":"PHASE1","title":"Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma","status":"TERMINATED","sponsor":"South Plains Oncology Consortium","startDate":"2014-05","conditions":"Recurrent Neuroblastoma, Neuroblastoma","enrollment":4},{"nctId":"NCT02075177","phase":"","title":"Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma","status":"NO_LONGER_AVAILABLE","sponsor":"South Plains Oncology Consortium","startDate":"","conditions":"Recurrent Neuroblastoma, Neuroblastoma","enrollment":""},{"nctId":"NCT01535157","phase":"PHASE1, PHASE2","title":"Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"South Plains Oncology Consortium","startDate":"2012-02","conditions":"Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary","enrollment":12},{"nctId":"NCT00589381","phase":"PHASE1","title":"Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-08","conditions":"Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["4-HPR","Fenretinide","4-HPR/LXS","Fenretinide/LXS"],"phase":"phase_2","status":"active","brandName":"Fenretinide Lym-X-Sorb Oral Powder","genericName":"Fenretinide Lym-X-Sorb Oral Powder","companyName":"South Plains Oncology Consortium","companyId":"south-plains-oncology-consortium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fenretinide is a synthetic retinoid that induces apoptosis in cancer cells. Used for Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}